Cancer proteomics

Mass Spectrometry Reviews

Volumn 31, Issue 5, 2012, Pages 583-605

  Tan, Hwee Tong ^a   Lee, Yie Hou ^b   Chung, Maxey C M ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

biomarkers; cancer; proteomics; quantitative proteomics strategies

Indexed keywords

CANCER; CANCER BIOLOGY; CELL LINES; DRUG TARGETS; EARLY DIAGNOSIS; FUNCTIONAL PROTEINS; HIGH-THROUGHPUT METHOD; PERSONALIZED MEDICINES; PROTEIN IDENTIFICATION; PROTEOMICS; PROTEOMICS TECHNOLOGY; QUANTITATIVE PROTEOMICS; TUMORIGENESIS;

BIOMARKERS; CELL CULTURE; DIAGNOSIS; DISEASES; DRUG THERAPY; INNOVATION; MOLECULAR BIOLOGY; TISSUE;

PROTEINS;

DIAGNOSTIC AGENT; PROTEOME; TUMOR MARKER;

ANIMAL; ARTICLE; GENETICS; GENOMICS; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; NEOPLASM; PROTEIN MICROARRAY; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENOMICS; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865117707     PISSN: 02777037     EISSN: 10982787     Source Type: Journal    
DOI: 10.1002/mas.20356     Document Type: Article

References (293)

1. Abbott A,. 1999. A post-genomic challenge: Learning to read patterns of protein synthesis. Nature 402: 715-720;.
2. Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M,. 2010. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics 10: 470-481;.
3. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, Rodriguez H, Rudnick PA, Smith D, Tabb DL, Tegeler TJ, Variyath AM, Vega-Montoto LJ, Wahlander A, Waldemarson S, Wang M, Whiteaker JR, Zhao L, Anderson NL, Fisher SJ, Liebler DC, Paulovich AG, Regnier FE, Tempst P, Carr SA,. 2009. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27: 633-641;.
4. Aebersold R, Mann M,. 2003. Mass spectrometry-based proteomics. Nature 422: 198-207;. (Pubitemid 36362757)
5. Aggelis V, Craven RA, Peng J, Harnden P, Cairns DA, Maher ER, Tonge R, Selby PJ, Banks RE,. 2009. Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics 9: 2118-2130;.
6. Ahrens CH, Brunner E, Qeli E, Basler K, Aebersold R,. 2010. Generating and navigating proteome maps using mass spectrometry. Nat Rev Mol Cell Biol 11: 789-801;.
7. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER,. 2004. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10: 7500-7510;. (Pubitemid 39557511)
8. Amon LM, Law W, Fitzgibbon MP, Gross JA, O'Briant K, Peterson A, Drescher C, Martin DB, McIntosh M,. 2010. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS ONE 5: e11137.
9. Anderson NL,. 2010. The clinical plasma proteome: A survey of clinical assays for proteins in plasma and serum. Clin Chem 56: 177-185;.
10. Anderson NL, Anderson NG,. 2002. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867;.
11. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A,. 2004. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3: 311-326;.
12. Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC,. 2006. Proteomics in clinical trials and practice: Present uses and future promise. Mol Cell Proteomics 5: 1819-1829;. (Pubitemid 44688191)
13. Baggerly KA, Morris JS, Edmonson SR, Coombes KR,. 2005. Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97: 307-309;. (Pubitemid 40310279)
14. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, Selby PJ,. 2000. Proteomics: New perspectives, new biomedical opportunities. Lancet 356: 1749-1756;.
15. Bantscheff M, Boesche M, Eberhard D, Matthieson T, Sweetman G, Kuster B,. 2008. Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer. Mol Cell Proteomics 7: 1702-1713;.
16. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE, Pantel K, Peter-Katalinic J, Brandt BH,. 2009. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 8: 2004-2014;.
17. Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP,. 2006. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24: 1285-1292;. (Pubitemid 44564776)
18. Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Hofler H,. 2007. Quantitative protein analysis from formalin-fixed tissues: Implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 211: 370-378;. (Pubitemid 46172713)
19. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, Laronga C,. 2004. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11: 907-914;. (Pubitemid 40486676)
20. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S,. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824;.
21. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, Sechi S, Nilsson T, Bergeron JJ,. 2009. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods 6: 423-430;.
22. Bi X, Lin Q, Foo TW, Joshi S, You T, Shen HM, Ong CN, Cheah PY, Eu KW, Hew CL,. 2006. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: Mechanism of tumorigenesis. Mol Cell Proteomics 5: 1119-1130;. (Pubitemid 43985935)
23. Blume-Jensen P, Hunter T,. 2001. Oncogenic kinase signalling. Nature 411: 355-365;. (Pubitemid 32467045)
24. Boersema PJ, Aye TT, van Veen TA, Heck AJ, Mohammed S,. 2008. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. Proteomics 8: 4624-4632;.
25. Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJ,. 2009. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc 4: 484-494;.
26. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, Liotta LA,. 1997. Laser capture microdissection: Molecular analysis of tissue. Science 278: 1481, 1483.
27. Borrebaeck CA,. 2006. Antibody microarray-based oncoproteomics. Expert Opin Biol Ther 6: 833-838;. (Pubitemid 44174215)
28. Boschetti E, Righetti PG,. 2009. The art of observing rare protein species in proteomes with peptide ligand libraries. Proteomics 9: 1492-1510;.
29. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM,. 2010. Antibody-based proteomics: Fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 10: 605-617;.
30. Butcher EC, Berg EL, Kunkel EJ,. 2004. Systems biology in drug discovery. Nat Biotechnol 22: 1253-1259;. (Pubitemid 39336778)
31. Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P,. 2005. Towards discovery-driven translational research in breast cancer. FEBS J 272: 2-15;. (Pubitemid 40083062)
32. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ,. 2004. Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 10: 1390-1396;. (Pubitemid 40022723)
33. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P,. 2003. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369;. (Pubitemid 36957839)
34. Chen CH,. 2008. Review of a current role of mass spectrometry for proteome research. Anal Chim Acta 624: 16-36;.
35. Chen N, Sun W, Deng X, Hao Y, Chen X, Xing B, Jia W, Ma J, Wei H, Zhu Y, Qian X, Jiang Y, He F,. 2008. Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics 8: 5108-5118;.
36. Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, Lane Z, Crispin DA, Goodlett DR, Aebersold R, Bronner MP,. 2007. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 6: 1331-1342;. (Pubitemid 47365432)
37. Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP, Aebersold R, Brentnall TA,. 2005. Pancreatic cancer proteome: The proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129: 1187-1197;. (Pubitemid 41446859)
38. Chen X, Jorgenson E, Cheung ST,. 2009. New tools for functional genomic analysis. Drug Discov Today 14: 754-760;.
39. Chenau J, Michelland S, de Fraipont F, Josserand V, Coll JL, Favrot MC, Seve M,. 2009. The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: Application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res 8: 4579-4591;.
40. Chernushevich IV, Loboda AV, Thomson BA,. 2001. An introduction to quadrupole-time-of-flight mass spectrometry. J Mass Spectrom 36: 849-865;. (Pubitemid 32827436)
41. Chin L, Gray JW,. 2008. Translating insights from the cancer genome into clinical practice. Nature 452: 553-563;. (Pubitemid 351483369)
42. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z, Cohen L, Danon T, Perzov N, Alon U,. 2008. Dynamic proteomics of individual cancer cells in response to a drug. Science 322: 1511-1516;.
43. Cohen P,. 2002. The origins of protein phosphorylation. Nat Cell Biol 4: E127-E130;. (Pubitemid 34521025)
44. Collins FS, Barker AD,. 2007. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 296: 50-57;.
45. Consortium IHGS,. 2004. Finishing the euchromatic sequence of the human genome. Nature 431: 931-945;.
46. Costenoble R, Picotti P, Reiter L, Stallmach R, Heinemann M, Sauer U, Aebersold R,. 2011. Comprehensive quantitative analysis of central carbon and amino-acid metabolism in Saccharomyces cerevisiae under multiple conditions by targeted proteomics. Mol Syst Biol 7: 464.
47. Couzin J,. 2004. Genomics. Consensus emerges on HapMap strategy. Science 304: 671-673;. (Pubitemid 38560853)
48. Cox J, Mann M,. 2007. Is proteomics the new genomics ? Cell 130: 395-398;.
49. Cunningham C Jr, Glish GL, Burinsky DJ,. 2006. High amplitude short time excitation: A method to form and detect low mass product ions in a quadrupole ion trap mass spectrometer. J Am Soc Mass Spectrom 17: 81-84;. (Pubitemid 43031392)
50. Cutler P,. 2003. Protein arrays: The current state-of-the-art. Proteomics 3: 3-18;. (Pubitemid 36151063)
51. Davis MA, Hanash S,. 2006. High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy. Breast Cancer Res 8: 217.
52. Dengjel J, Akimov V, Olsen JV, Bunkenborg J, Mann M, Blagoev B, Andersen JS,. 2007. Quantitative proteomic assessment of very early cellular signaling events. Nat Biotechnol 25: 566-568;. (Pubitemid 46834842)
53. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP,. 2008. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 105: 10762-10767;.
54. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, Chen S, Eddes J, Loevenich SN, Aebersold R,. 2006. The PeptideAtlas project. Nucleic Acids Res 34: D655-D658;.
55. DeSouza L, Diehl G, Rodrigues MJ, Guo J, Romaschin AD, Colgan TJ, Siu KW,. 2005. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 4: 377-386;. (Pubitemid 40548142)
56. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM,. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826;. (Pubitemid 32801464)
57. Di Girolamo F, Boschetti E, Chung MC, Guadagni F, Righetti PG,. 2011. " Proteomineering" or not? The debate on biomarker discovery in sera continues. J Proteomics 74: 589-594;.
58. Diamandis EP,. 2003. Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics ? Clin Chem 49: 1272-1275;. (Pubitemid 36900611)
59. Diamandis EP,. 2004. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. Mol Cell Proteomics 3: 367-378;. (Pubitemid 38702090)
60. Dolinoy DC, Jirtle RL,. 2008. Environmental epigenomics in human health and disease. Environ Mol Mutagen 49: 4-8;. (Pubitemid 351293007)
61. Doucet A, Butler GS, Rodriguez D, Prudova A, Overall CM,. 2008. Metadegradomics: Toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteomics 7: 1925-1951;.
62. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ,. 2006. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 5: 1957-1967;. (Pubitemid 44688203)
63. Dupuy L, Gauthier C, Durand G, Musnier A, Heitzler D, Herledan A, Sakanyan V, Crepieux P, Reiter E,. 2009. A highly sensitive near-infrared fluorescent detection method to analyze signalling pathways by reverse-phase protein array. Proteomics 9: 5446-5454;.
64. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA,. 1996. Laser capture microdissection. Science 274: 998-1001;. (Pubitemid 26398425)
65. Ernoult E, Bourreau A, Gamelin E, Guette C,. 2010. A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J Biomed Biotechnol 2010: 927917.
66. Ernoult E, Gamelin E, Guette C,. 2008. Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci 6: 27.
67. Espina V, Dettloff KA, Cowherd S, Petricoin EF III, Liotta LA,. 2004. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 4: 83-93;. (Pubitemid 38057269)
68. Ewing B, Green P,. 2000. Analysis of expressed sequence tags indicates 35,000 human genes. Nat Genet 25: 232-234;. (Pubitemid 30395000)
69. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM,. 2008. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.
70. Farina A, Dumonceau JM, Lescuyer P,. 2009. Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev Proteomics 6: 285-301;.
71. Feinberg AP, Ohlsson R, Henikoff S,. 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33;. (Pubitemid 41828945)
72. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Sun W, Wang H, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermitzakis ET, Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, Chretien YR, Maller J, McCarroll S, Patterson N, Pe'er I, Price A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, Sham PC, Varilly P, Stein LD, Krishnan L, Smith AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, Clarke G, Evans DM, Morris AP, Weir BS, Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Peiffer A, Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers BM, Foster MW, Clayton EW, Watkin J, Muzny D, Nazareth L, Sodergren E, Weinstock GM, Yakub I, Birren BW, Wilson RK, Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg JC, L'Archeveque P, Bellemare G, Saeki K, An D, Fu H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart J,. 2007. A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861;. (Pubitemid 47598626)
73. Fusaro VA, Mani DR, Mesirov JP, Carr SA,. 2009. Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol 27: 190-198;.
74. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M,. 2010. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods 7: 383-385;.
75. Geiss-Friedlander R, Melchior F,. 2007. Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol 8: 947-956;. (Pubitemid 350176509)
76. Giles NM, Giles GI, Jacob C,. 2003. Multiple roles of cysteine in biocatalysis. Biochem Biophys Res Commun 300: 1-4;. (Pubitemid 36050058)
77. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ,. 2006. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7: 278.
78. Goh WW, Lee YH, Zubaidah RM, Jin J, Dong D, Lin Q, Chung MC, Wong L,. 2011. Network-based pipeline for analyzing MS data: An application toward liver cancer. J Proteome Res 10: 2261-2272;.
79. Gorg A, Weiss W, Dunn MJ,. 2004. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4: 3665-3685;. (Pubitemid 39657447)
80. Gramolini AO, Kislinger T, Alikhani-Koopaei R, Fong V, Thompson NJ, Isserlin R, Sharma P, Oudit GY, Trivieri MG, Fagan A, Kannan A, Higgins DG, Huedig H, Hess G, Arab S, Seidman JG, Seidman CE, Frey B, Perry M, Backx PH, Liu PP, MacLennan DH, Emili A,. 2008. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics 7: 519-533;. (Pubitemid 351472462)
81. Greenbaum D, Luscombe NM, Jansen R, Qian J, Gerstein M,. 2001. Interrelating different types of genomic data, from proteome to secretome: Oming in on function. Genome Res 11: 1463-1468;. (Pubitemid 32894671)
82. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A, Pandey A,. 2006. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171;. (Pubitemid 43169348)
83. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF,. 2003. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3: 2142-2146;. (Pubitemid 37414080)
84. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R,. 1999a. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17: 994-999;. (Pubitemid 29474856)
85. Gygi SP, Rochon Y, Franza BR, Aebersold R,. 1999b. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730;. (Pubitemid 29098230)
86. Haab BB,. 2006. Applications of antibody array platforms. Curr Opin Biotechnol 17: 415-421;. (Pubitemid 44163462)
87. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP,. 2006. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8: R25.
88. Hakomori S,. 1996. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56: 5309-5318;. (Pubitemid 27011703)
89. Halligan BD, Ruotti V, Jin W, Laffoon S, Twigger SN, Dratz EA,. 2004. ProMoST (Protein Modification Screening Tool): A web-based tool for mapping protein modifications on two-dimensional gels. Nucleic Acids Res 32: W638-W644;. (Pubitemid 38997414)
90. Han DK, Eng J, Zhou H, Aebersold R,. 2001. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 19: 946-951;. (Pubitemid 32947573)
91. Hanahan D, Weinberg RA,. 2000. The hallmarks of cancer. Cell 100: 57-70;. (Pubitemid 30046295)
92. Hanash SM,. 2000. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: Current status. Electrophoresis 21: 1202-1209;. (Pubitemid 30230784)
93. Hanash SM, Baier LJ, McCurry L, Schwartz SA,. 1986. Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. Proc Natl Acad Sci USA 83: 807-811;. (Pubitemid 16035564)
94. Hanash SM, Pitteri SJ, Faca VM,. 2008. Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579;. (Pubitemid 351483371)
95. Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J,. 2005. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res 11: 2969-2973;. (Pubitemid 40525200)
96. Harsha HC, Molina H, Pandey A,. 2008. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc 3: 505-516;. (Pubitemid 351372235)
97. Hawkins RD, Hon GC, Ren B,. 2010. Next-generation genomics: An integrative approach. Nat Rev Genet 11: 476-486;.
98. Helenius A, Aebi M,. 2001. Intracellular functions of N-linked glycans. Science 291: 2364-2369;. (Pubitemid 32231791)
99. Heller M, Michel PE, Morier P, Crettaz D, Wenz C, Tissot JD, Reymond F, Rossier JS,. 2005. Two-stage Off-Gel isoelectric focusing: Protein followed by peptide fractionation and application to proteome analysis of human plasma. Electrophoresis 26: 1174-1188;. (Pubitemid 40514809)
100. Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, Wong CH, Wong CY, Shah N, Lim YP,. 2009. Novel breast cancer metastasis-associated proteins. J Proteome Res 8: 583-594;.
101. Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB,. 2005. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 4: 1741-1753;. (Pubitemid 41749267)
102. Hoving S, Voshol H, van Oostrum J,. 2000. Towards high performance two-dimensional gel electrophoresis using ultrazoom gels. Electrophoresis 21: 2617-2621;. (Pubitemid 30646296)
103. Hsu JL, Huang SY, Chow NH, Chen SH,. 2003. Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem 75: 6843-6852;.
104. Hu S, Loo JA, Wong DT,. 2006. Human body fluid proteome analysis. Proteomics 6: 6326-6353;. (Pubitemid 44935518)
105. Hu X, Zhang Y, Zhang A, Li Y, Zhu Z, Shao Z, Zeng R, Xu LX,. 2009. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology. Omics 13: 291-300;.
106. Huang L, Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, Amunngama R, Hagler RA, Pisano MR, Zhang WW, Fang X,. 2005. Immunoaffinity separation of plasma proteins by IgY microbeads: Meeting the needs of proteomic sample preparation and analysis. Proteomics 5: 3314-3328;. (Pubitemid 41192038)
107. Huang Y, Sadee W,. 2003. Drug sensitivity and resistance genes in cancer chemotherapy: A chemogenomics approach. Drug Discov Today 8: 356-363;. (Pubitemid 36398163)
108. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M,. 2007. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 104: 17494-17499;. (Pubitemid 350219866)
109. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, Bumgarner R, Goodlett DR, Aebersold R, Hood L,. 2001. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292: 929-934;. (Pubitemid 32422490)
110. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, Mann M,. 2005a. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4: 1265-1272;. (Pubitemid 41448714)
111. Ishihama Y, Sato T, Tabata T, Miyamoto N, Sagane K, Nagasu T, Oda Y,. 2005b. Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards. Nat Biotechnol 23: 617-621;. (Pubitemid 41724902)
112. Issaq H, Veenstra T,. 2008. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): Advances and perspectives. Biotechniques 44: 697-698;, 700.
113. Jain KK,. 2004. Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 1: 49-455;.
114. Jiang R, Duan J, Windemuth A, Stephens JC, Judson R, Xu C,. 2003. Genome-wide evaluation of the public SNP databases. Pharmacogenomics 4: 779-789;. (Pubitemid 37428364)
115. Johnson SA, Hunter T,. 2005. Kinomics: Methods for deciphering the kinome. Nat Methods 2: 17-25;. (Pubitemid 41131053)
116. Jones P, Cote RG, Cho SY, Klie S, Martens L, Quinn AF, Thorneycroft D, Hermjakob H,. 2008. PRIDE: New developments and new datasets. Nucleic Acids Res 36: D878-D883;. (Pubitemid 351149839)
117. Jones PA, Baylin SB,. 2007. The epigenomics of cancer. Cell 128: 683-692;. (Pubitemid 46273572)
118. Jourdain S, Bulman A, Dalmasso E,. 2010. The lucid proteomics system for top-down biomarker research. Arch Physiol Biochem 116: 158-162;.
119. Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, Kasai K, Takahashi N, Isobe T,. 2003. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol 21: 667-672;. (Pubitemid 36638094)
120. Kallioniemi A,. 2008. CGH microarrays and cancer. Curr Opin Biotechnol 19: 36-40;.
121. Kang UB, Ahn Y, Lee JW, Kim YH, Kim J, Yu MH, Noh DY, Lee C,. 2010a. Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. BMC Cancer 10: 114.
122. Kang UB, Yeom J, Kim H, Lee C,. 2010b. Quantitative analysis of mTRAQ-labeled proteome using full MS scans. J Proteome Res 9: 3750-3758;.
123. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N,. 2004. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95: 377-384;. (Pubitemid 38832679)
124. Keshamouni VG, Jagtap P, Michailidis G, Strahler JR, Kuick R, Reka AK, Papoulias P, Krishnapuram R, Srirangam A, Standiford TJ, Andrews PC, Omenn GS,. 2009. Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res 8: 35-47;.
125. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA,. 2007. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6: 2212-2229;.
126. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, Takagi T, Nakamura Y,. 2001. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474-6479;. (Pubitemid 32783254)
127. Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD,. 2008. Genome-wide association studies: Progress and potential for drug discovery and development. Nat Rev Drug Discov 7: 221-230;. (Pubitemid 351321233)
128. Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, Ferrige A, Alecio R, Borowsky AD, Sulaimon S, Lebrilla CB, Miyamoto S,. 2007. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 6: 43-55;. (Pubitemid 46152690)
129. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK,. 2009. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 877: 1229-1239;.
130. Klose J,. 1975. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26: 231-243;.
131. Kolch W, Pitt A,. 2010. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 10: 618-629;.
132. Kopf E, Zharhary D,. 2007. Antibody arraysâAn emerging tool in cancer proteomics. Int J Biochem Cell Biol 39: 1305-1317;. (Pubitemid 47031048)
133. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R,. 2005. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5: 4589-4596;. (Pubitemid 41739936)
134. Kubota K, Anjum R, Yu Y, Kunz RC, Andersen JN, Kraus M, Keilhack H, Nagashima K, Krauss S, Paweletz C, Hendrickson RC, Feldman AS, Wu CL, Rush J, Villen J, Gygi SP,. 2009. Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nat Biotechnol 27: 933-940;.
135. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B,. 2004. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 4: 1175-1186;. (Pubitemid 38445974)
136. Kulasingam V, Diamandis EP,. 2007. Proteomics analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. Mol Cell Proteomics 6: 1997-2011;. (Pubitemid 350201873)
137. Kulis M, Esteller M,. 2010. DNA methylation and cancer. Adv Genet 70: 27-56;.
138. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blocker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowski J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K,
139. Lange V, Malmstrom JA, Didion J, King NL, Johansson BP, Schafer J, Rameseder J, Wong CH, Deutsch EW, Brusniak MY, Buhlmann P, Bjorck L, Domon B, Aebersold R,. 2008. Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol Cell Proteomics 7: 1489-1500;.
140. Larsen MR, Jensen SS, Jakobsen LA, Heegaard NH,. 2007. Exploring the sialiome using titanium dioxide chromatography and mass spectrometry. Mol Cell Proteomics 6: 1778-1787;. (Pubitemid 350031679)
141. Latterich M, Abramovitz M, Leyland-Jones B,. 2008. Proteomics: New technologies and clinical applications. Eur J Cancer 44: 2737-2741;.
142. Lee HJ, Na K, Choi EY, Kim KS, Kim H, Paik YK,. 2010. Simple method for quantitative analysis of N-linked glycoproteins in hepatocellular carcinoma specimens. J Proteome Res 9: 308-318;.
143. Lehmann R, Melle C, Escher N, von Eggeling F,. 2005. Detection and identification of protein interactions of S100 proteins by ProteinChip technology. J Proteome Res 4: 1717-1721;. (Pubitemid 41464799)
144. Leroy C, Fialin C, Sirvent A, Simon V, Urbach S, Poncet J, Robert B, Jouin P, Roche S,. 2009. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res 69: 2279-2286;.
145. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB,. 2010a. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6: 291-299;.
146. Li SL, Ye F, Cai WJ, Hu HD, Hu P, Ren H, Zhu FF, Zhang DZ,. 2010b. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem 109: 625-633;.
147. Liang CR, Leow CK, Neo JC, Tan GS, Lo SL, Lim JW, Seow TK, Lai PB, Chung MC,. 2005. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 5: 2258-2271;. (Pubitemid 40770587)
148. Liang P, Pardee AB,. 2003. Analysing differential gene expression in cancer. Nat Rev Cancer 3: 869-876;. (Pubitemid 37376983)
149. Lill J,. 2003. Proteomic tools for quantitation by mass spectrometry. Mass Spectrom Rev 22: 182-194;.
150. Lin B, White JT, Wu J, Lele S, Old LJ, Hood L, Odunsi K,. 2009. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl 3: 853-861;.
151. Liotta L, Petricoin E,. 2000. Molecular profiling of human cancer. Nat Rev Genet 1: 48-56;.
152. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, Petricoin EF III., 2003. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3: 317-325;. (Pubitemid 38340301)
153. Liotta LA, Kohn EC,. 2001. The microenvironment of the tumour-host interface. Nature 411: 375-379;.
154. Liu H, Sadygov RG, Yates JR III., 2004. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76: 4193-4201;. (Pubitemid 38943698)
155. Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, Camp DG II, Smith RD,. 2006. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 5: 2167-2174;. (Pubitemid 44817028)
156. Lopez-Otin C, Overall CM,. 2002. Protease degradomics: A new challenge for proteomics. Nat Rev Mol Cell Biol 3: 509-519;. (Pubitemid 34733432)
157. Loster K, Kannicht C,. 2008. 2-dimensional electrophoresis: Detection of glycosylation and influence on spot pattern. Methods Mol Biol 446: 199-214;.
158. Lowe JB, Marth JD,. 2003. A genetic approach to mammalian glycan function. Annu Rev Biochem 72: 643-691;. (Pubitemid 36930456)
159. MacBeath G,. 2002. Protein microarrays and proteomics. Nat Genet 32 (Suppl): 526-532;. (Pubitemid 35435157)
160. Macek B, Mann M, Olsen JV,. 2009. Global and site-specific quantitative phosphoproteomics: Principles and applications. Annu Rev Pharmacol Toxicol 49: 199-221;.
161. Malmstrom J, Beck M, Schmidt A, Lange V, Deutsch EW, Aebersold R,. 2009. Proteome-wide cellular protein concentrations of the human pathogen Leptospira interrogans. Nature 460: 762-765;.
162. Mann M,. 2006. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7: 952-958;. (Pubitemid 44871421)
163. Mann M, Kelleher NL,. 2008. Precision proteomics: The case for high resolution and high mass accuracy. Proc Natl Acad Sci USA 105: 18132-18138;.
164. Mead JA, Bianco L, Ottone V, Barton C, Kay RG, Lilley KS, Bond NJ, Bessant C,. 2009. MRMaid, the web-based tool for designing multiple reaction monitoring (MRM) transitions. Mol Cell Proteomics 8: 696-705;.
165. Monetti M, Nagaraj N, Sharma K, Mann M,. 2011. Large-scale phosphosite quantification in tissues by a spike-in SILAC method. Nature Methods 8: 655-658;.
166. Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y,. 2010. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 277: 95-105;.
167. Nettikadan S, Radke K, Johnson J, Xu J, Lynch M, Mosher C, Henderson E,. 2006. Detection and quantification of protein biomarkers from fewer than 10cells. Mol Cell Proteomics 5: 895-901;. (Pubitemid 43792798)
168. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW,. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527;. (Pubitemid 44854747)
169. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A,. 2009. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br J Cancer 100: 1603-1607;.
170. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Espina V, Munson PJ, Petricoin E III, Liotta LA, Weinstein JN,. 2003. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 100: 14229-14234;. (Pubitemid 37499219)
171. Nissum M, Kuhfuss S, Hauptmann M, Obermaier C, Sukop U, Wildgruber R, Weber G, Eckerskorn C, Malmstrom J,. 2007. Two-dimensional separation of human plasma proteins using iterative free-flow electrophoresis. Proteomics 7: 4218-4227;. (Pubitemid 350250467)
172. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S,. 2002. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72;. (Pubitemid 34436727)
173. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN,. 2003. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607;. (Pubitemid 36373650)
174. O'Farrell PH,. 1975. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250: 4007-4021;.
175. Oda Y, Huang K, Cross FR, Cowburn D, Chait BT,. 1999. Accurate quantitation of protein expression and site-specific phosphorylation. Proc Natl Acad Sci USA 96: 6591-6596;. (Pubitemid 29274927)
176. Oda Y, Nagasu T, Chait BT,. 2001. Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol 19: 379-382;. (Pubitemid 32275350)
177. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG,. 2009. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34: 115-131;.
178. Olsen JV, Macek B, Lange O, Makarov A, Horning S, Mann M,. 2007. Higher-energy C-trap dissociation for peptide modification analysis. Nature Methods 4: 709-712;. (Pubitemid 47338163)
179. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M,. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1: 376-386;.
180. Ong SE, Mann M,. 2005. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1: 252-262;.
181. Ong SE, Mann M,. 2006. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 1: 2650-2660;.
182. Orntoft TF, Vestergaard EM,. 1999. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 20: 362-371;. (Pubitemid 29125024)
183. Palmisano G, Lendal SE, Engholm-Keller K, Leth-Larsen R, Parker BL, Larsen MR,. 2010. Selective enrichment of sialic acid-containing glycopeptides using titanium dioxide chromatography with analysis by HILIC and mass spectrometry. Nat Protoc 5: 1974-1982;.
184. Palmisano G, Lendal SE, Larsen MR,. 2011. Titanium dioxide enrichment of sialic acid-containing glycopeptides. Methods Mol Biol 753: 309-322;.
185. Parikh K, Peppelenbosch MP,. 2010. Kinome profiling of clinical cancer specimens. Cancer Res 70: 2575-2578;.
186. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze SK,. 2010. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 9: 1085-1099;.
187. Pawlak M, Schick E, Bopp MA, Schneider MJ, Oroszlan P, Ehrat M,. 2002. Zeptosens' protein microarrays: A novel high performance microarray platform for low abundance protein analysis. Proteomics 2: 383-393;. (Pubitemid 34429356)
188. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM,. 2005. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 89: 149-157;. (Pubitemid 40253557)
189. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM,. 2006. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 6: 68.
190. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R,. 2003. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13: 457-470;. (Pubitemid 36665420)
191. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D,. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752;.
192. Perry RH, Cooks RG, Noll RJ,. 2008. Orbitrap mass spectrometry: Instrumentation, ion motion and applications. Mass Spectrom Rev 27: 661-699;.
193. Petricoin EF III, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW Jr, Zoon KC, Sistare FD,. 2002a. Medical applications of microarray technologies: A regulatory science perspective. Nat Genet 32 (Suppl): 474-479;. (Pubitemid 35435149)
194. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA,. 2002b. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577;. (Pubitemid 34178440)
195. Petricoin EF, Liotta LA,. 2004. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15: 24-30;. (Pubitemid 38224245)
196. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L, Jaworska E, Lee CF, Blinco D, Okoniewski MJ, Miller CJ, Bitton DA, Spooncer E, Whetton AD,. 2008. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 7: 853-863;. (Pubitemid 351737087)
197. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP,. 2009. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 8: 2746-2758;.
198. Powlesland AS, Hitchen PG, Parry S, Graham SA, Barrio MM, Elola MT, Mordoh J, Dell A, Drickamer K, Taylor ME,. 2009. Targeted glycoproteomic identification of cancer cell glycosylation. Glycobiology 19: 899-909;.
199. Qiu H, Wang Y,. 2008. Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells. J Proteome Res 7: 1904-1915;.
200. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, Krasnoselsky AL, Randolph TW, Omenn GS, Edelstein C, Barnett MJ, Thornquist MD, Goodman GE, Brenner DE, Feng Z, Hanash SM,. 2008. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 26: 5060-5066;.
201. Qiu R, Regnier FE,. 2005. Comparative glycoproteomics of N-linked complex-type glycoforms containing sialic acid in human serum. Anal Chem 77: 7225-7231;. (Pubitemid 41681388)
202. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW,. 2008. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7: 1162-1173;. (Pubitemid 351943962)
203. Rifai N, Gillette MA, Carr SA,. 2006. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 24: 971-983;. (Pubitemid 44215392)
204. Rong Y, Jin D, Hou C, Hu J, Wu W, Ni X, Wang D, Lou W,. 2010. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: Up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 10: 68.
205. Rosenfeld R, Bangio H, Gerwig GJ, Rosenberg R, Aloni R, Cohen Y, Amor Y, Plaschkes I, Kamerling JP, Maya RB,. 2007. A lectin array-based methodology for the analysis of protein glycosylation. J Biochem Biophys Methods 70: 415-426;. (Pubitemid 46356573)
206. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ,. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3: 1154-1169;.
207. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ,. 2005. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94-101;. (Pubitemid 41724631)
208. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas AM, Van't Veer LJ, Tollenaar R,. 2011. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17-24;.
209. Sanchez-Carbayo M,. 2006. Antibody arrays: Technical considerations and clinical applications in cancer. Clin Chem 52: 1651-1659;. (Pubitemid 44330697)
210. Sanchez-Carbayo M,. 2010. Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol 31: 103-112;.
211. Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL, Caprioli RM,. 2008. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res 7: 1500-1507;.
212. Sandhu C, Hewel JA, Badis G, Talukder S, Liu J, Hughes TR, Emili A,. 2008. Evaluation of data-dependent versus targeted shotgun proteomic approaches for monitoring transcription factor expression in breast cancer. J Proteome Res 7: 1529-1541;.
213. Satoh H, Ishikawa H, Kamma H, Yamashita YT, Takahashi H, Ohtsuka M, Hasegawa S,. 1997. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: Correlation with distant metastasis and survival. Clin Cancer Res 3: 495-499;. (Pubitemid 27211824)
214. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN,. 2000. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244;. (Pubitemid 30132190)
215. Schiess R, Wollscheid B, Aebersold R,. 2009. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3: 33-44;.
216. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H,. 2006. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314: 304-308;. (Pubitemid 44571976)
217. Schirle M, Heurtier MA, Kuster B,. 2003. Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2: 1297-1305;.
218. Schmidt A, Claassen M, Aebersold R,. 2009. Directed mass spectrometry: Towards hypothesis-driven proteomics. Curr Opin Chem Biol 13: 510-517;.
219. Schnolzer M, Jedrzejewski P, Lehmann WD,. 1996. Protease-catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis 17: 945-953;.
220. Schrimpf SP, Weiss M, Reiter L, Ahrens CH, Jovanovic M, Malmstrom J, Brunner E, Mohanty S, Lercher MJ, Hunziker PE, Aebersold R, von Mering C, Hengartner MO,. 2009. Comparative functional analysis of the Caenorhabditis elegans and Drosophila melanogaster proteomes. PLoS Biol 7: e48.
221. Schuster SC,. 2008. Next-generation sequencing transforms today's biology. Nat Methods 5: 16-18;.
222. Seet BT, Dikic I, Zhou MM, Pawson T,. 2006. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7: 473-483;. (Pubitemid 44036453)
223. Selevsek N, Matondo M, Sanchez Carbayo M, Aebersold R, Domon B,. 2011. Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics 11: 1135-1147;.
224. Shalon D, Smith SJ, Brown PO,. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 6: 639-645;. (Pubitemid 26275868)
225. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF III, Wulfkuhle JD,. 2005. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4: 346-355;. (Pubitemid 40590555)
226. Shiio Y, Aebersold R,. 2006. Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc 1: 139-145;.
227. Shinawi M, Cheung SW,. 2008. The array CGH and its clinical applications. Drug Discov Today 13: 760-770;.
228. Simpson AJ,. 2009. Sequence-based advances in the definition of cancer-associated gene mutations. Curr Opin Oncol 21: 47-52;.
229. Sjoblom T,. 2008. Systematic analyses of the cancer genome: Lessons learned from sequencing most of the annotated human protein-coding genes. Curr Opin Oncol 20: 66-71;. (Pubitemid 350190983)
230. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET,. 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398;. (Pubitemid 37071889)
231. Spurrier B, Honkanen P, Holway A, Kumamoto K, Terashima M, Takenoshita S, Wakabayashi G, Austin J, Nishizuka S,. 2008. Protein and lysate array technologies in cancer research. Biotechnol Adv 26: 361-369;.
232. Stattin P, Hakama M,. 2003. Correspondence re: B-L. Adam et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614;, 2002. Cancer Res 63:2701; author reply 2701-2702.
233. Steen H, Mann M,. 2004. The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol Cell Biol 5: 699-711;. (Pubitemid 39208180)
234. Stensballe A, Jensen ON, Olsen JV, Haselmann KF, Zubarev RA,. 2000. Electron capture dissociation of singly and multiply phosphorylated peptides. Rapid Commun Mass Spectrom 14: 1793-1800;.
235. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B,. 2006. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5: 433-443;.
236. Sun B, Ranish JA, Utleg AG, White JT, Yan X, Lin B, Hood L,. 2007. Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics. Mol Cell Proteomics 6: 141-149;. (Pubitemid 46152699)
237. Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiao Y, Jia W, Bi X, Lu N, Liu S, Qian X, Zhao X,. 2008. Quantitative proteomic signature of liver cancer cells: Tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res 7: 3847-3859;.
238. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF,. 2004. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 101: 9528-9533;. (Pubitemid 38869270)
239. Tan HT, Low J, Lim SG, Chung MC,. 2009. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276: 6880-6904;.
240. Tan HT, Tan S, Lin Q, Lim TK, Hew CL, Chung MC,. 2008. Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol Cell Proteomics 7: 1174-1185;. (Pubitemid 351943963)
241. Templin MF, Stoll D, Schrenk M, Traub PC, Vohringer CF, Joos TO,. 2002. Protein microarray technology. Trends Biotechnol 20: 160-166;. (Pubitemid 34242857)
242. Temporini C, Calleri E, Massolini G, Caccialanza G,. 2008. Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins. Mass Spectrom Rev 27: 207-236;. (Pubitemid 351547982)
243. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX,. 2008. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8: 241.
244. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE,. 2004. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 3: 960-969;. (Pubitemid 40361231)
245. Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F, Glas AM,. 2010. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 5: 129-138;.
246. Tonack S, Aspinall-O'Dea M, Jenkins RE, Elliot V, Murray S, Lane CS, Kitteringham NR, Neoptolemos JP, Costello E,. 2009. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics 73: 352-356;.
247. Unlu M, Morgan ME, Minden JS,. 1997. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 18: 2071-2077;. (Pubitemid 27501267)
248. Unwin RD, Griffiths JR, Leverentz MK, Grallert A, Hagan IM, Whetton AD,. 2005. Multiple reaction monitoring to identify sites of protein phosphorylation with high sensitivity. Mol Cell Proteomics 4: 1134-1144;. (Pubitemid 41223372)
249. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO,. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659;. (Pubitemid 47214727)
250. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH,. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536;. (Pubitemid 34130608)
251. VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF III, Liotta LA, Espina V,. 2008. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 7: 1902-1924;.
252. Venter JC,. 2003. A part of the human genome sequence. Science 299: 1183-1184;.
253. Verma M, Srivastava S,. 2003. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 163: 72-84; discussion 264-266.
254. Villen J, Beausoleil SA, Gerber SA, Gygi SP,. 2007. Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci USA 104: 1488-1493;. (Pubitemid 46214617)
255. Vogel C, Abreu Rde, Ko S, Le SY D, Shapiro BA, Burns SC, Sandhu D, Boutz DR, Marcotte EM, Penalva LO,. 2010. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol 6: 400.
256. Walsh G, Jefferis R,. 2006. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24: 1241-1252;. (Pubitemid 44564769)
257. Walter G, Bussow K, Lueking A, Glokler J,. 2002. High-throughput protein arrays: Prospects for molecular diagnostics. Trends Mol Med 8: 250-253;. (Pubitemid 34568374)
258. Washburn MP, Ulaszek R, Deciu C, Schieltz DM, Yates JR III., 2002. Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal Chem 74: 1650-1657;. (Pubitemid 34297605)
259. Washburn MP, Wolters D, Yates JR III., 2001. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19: 242-247;. (Pubitemid 32220565)
260. Watson RW, Kay EW, Smith D,. 2010. Integrating biobanks: Addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nat Rev Cancer 10: 646-651;.
261. Wei X, Li L,. 2009. Comparative glycoproteomics: Approaches and applications. Brief Funct Genomic Proteomic 8: 104-113;.
262. Weir B, Zhao X, Meyerson M,. 2004. Somatic alterations in the human cancer genome. Cancer Cell 6: 433-438;. (Pubitemid 39469978)
263. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM,. 2008. Applications of SELDI-MS technology in oncology. J Cell Mol Med 12: 1535-1547;.
264. White FM,. 2008. Quantitative phosphoproteomic analysis of signaling network dynamics. Curr Opin Biotechnol 19: 404-409;.
265. Wiese S, Reidegeld KA, Meyer HE, Warscheid B,. 2007. Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research. Proteomics 7: 340-350;. (Pubitemid 46293976)
266. Wiesner A,. 2004. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol 5: 45-67;. (Pubitemid 38404705)
267. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL,. 1996. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13: 19-50;.
268. Wrensch MR, Petrakis NL, Gruenke LD, Ernster VL, Miike R, King EB, Hauck WW,. 1990. Factors associated with obtaining nipple aspirate fluid: Analysis of 1428 women and literature review. Breast Cancer Res Treat 15: 39-51;. (Pubitemid 20139597)
269. Wu J, Smith LT, Plass C, Huang TH,. 2006. ChIP-chip comes of age for genome-wide functional analysis. Cancer Res 66: 6899-6902;. (Pubitemid 44197662)
270. Wulfkuhle J, Espina V, Liotta L, Petricoin E,. 2004. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 40: 2623-2632;. (Pubitemid 39487084)
271. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF III., 2003. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3: 2085-2090;. (Pubitemid 37414073)
272. Xiao Z, Li G, Chen Y, Li M, Peng F, Li C, Li F, Yu Y, Ouyang Y, Chen Z,. 2010. Quantitative proteomic analysis of formalin-fixed and paraffin-embedded nasopharyngeal carcinoma using iTRAQ labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. J Histochem Cytochem 58: 517-527;.
273. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ,. 2005. Proteomic patterns: Their potential for disease diagnosis. Mol Cell Endocrinol 230: 95-106;. (Pubitemid 40138974)
274. Xie X, Feng S, Vuong H, Liu Y, Goodison S, Lubman DM,. 2010. A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach. Electrophoresis 31: 1842-1852;.
275. Xiong L, Andrews D, Regnier F,. 2003. Comparative proteomics of glycoproteins based on lectin selection and isotope coding. J Proteome Res 2: 618-625;. (Pubitemid 38017106)
276. Xu BJ, Yan W, Jovanovic B, An AQ, Cheng N, Aakre ME, Yi Y, Eng J, Link AJ, Moses HL,. 2010. Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts. Proteomics 13: 2458-2470;.
277. Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR,. 2010. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res 9: 3073-3082;.
278. Yocum AK, Busch CM, Felix CA, Blair IA,. 2006. Proteomics-based strategy to identify biomarkers and pharmacological targets in leukemias with t(4;11) translocations. J Proteome Res 5: 2743-2753;. (Pubitemid 44595175)
279. Yue T, Haab BB,. 2009. Microarrays in glycoproteomics research. Clin Lab Med 29: 15-29;.
280. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y,. 2002. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62: 518-527;. (Pubitemid 34106426)
281. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatova NF,. 2006. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 5: 2909-2918;. (Pubitemid 44749209)
282. Zhang G, Fenyo D, Neubert TA,. 2008. Screening for EphB signaling effectors using SILAC with a linear ion trap-orbitrap mass spectrometer. J Proteome Res 7: 4715-4726;.
283. Zhang H, Yan W, Aebersold R,. 2004. Chemical probes and tandem mass spectrometry: A strategy for the quantitative analysis of proteomes and
284. Zhang J, Niu D, Sui J, Ching CB, Chen WN,. 2009. Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2cells by iTRAQ-coupled 2-D LC-MS/MS analysis: Insights on liver angiogenesis. Proteomics 9: 2836-2845;.
285. Zhang Z, Chan DW,. 2010. The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 19: 2995-2999;.
286. Zhao Y, Jensen ON,. 2009. Modification-specific proteomics: Strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 9: 4632-4641;.
287. Zhou H, Watts JD, Aebersold R,. 2001. A systematic approach to the analysis of protein phosphorylation. Nat Biotechnol 19: 375-378;. (Pubitemid 32275349)
288. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF III, Liotta LA, Veenstra TD, Conrads TP,. 2004. An investigation into the human serum "interactome ". Electrophoresis 25: 1289-1298;.
289. Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE,. 2010. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 10: 1029-1039;.
290. Zhu H, Snyder M,. 2003. Protein chip technology. Curr Opin Chem Biol 7: 55-63;. (Pubitemid 36126493)
291. Zieske LR,. 2006. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 57: 1501-1508;.
292. Zilberman D, Henikoff S,. 2007. Genome-wide analysis of DNA methylation patterns. Development 134: 3959-3965;. (Pubitemid 350269413)
293. Zwick E, Bange J, Ullrich A,. 2002. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8: 17-23;. (Pubitemid 34044674)